Merck Raises Annual Guidance Following Strong Q1 Keytruda Sales

Merck & Co. Inc. reported $7 billion in sales from its blockbuster drug Keytruda in the first quarter of 2026. Following an earnings beat that exceeded initial estimates, the company has officially raised its full-year financial guidance. The firm’s growth strategy remains heavily reliant on high R&D spending to mitigate risks stemming from upcoming patent expirations and market competition.

This robust performance comes amid intense competition in the Big Pharma space, where peer stocks such as Pfizer and Bristol Myers Squibb have shown relative price stability per market data. According to recent sector earnings reports, Merck’s focus on Keytruda and the Gardasil vaccine provides a competitive margin advantage over its rivals. Analysts suggest that the guidance raise reflects management's confidence in the R&D pipeline's ability to offset revenue gaps from future patent cliffs.

Investors should watch for growth sustainability ahead of key economic catalysts, including the U.S. Inflation Rate (CPI) data scheduled for release on May 12, 2026, which may impact healthcare sector financing costs. Additionally, the Fed Williams speech on the same day will provide further clarity on interest rate trajectories. R&D expenditure levels remain the primary metric for the stock's valuation as the company navigates long-term patent challenges.